-
November 16, 2012
With the election over, many investors assumed that one of the key risk events for U.S. markets was past us. ...
-
November 14, 2012
Shortly after announcing promising phase II data on its hepatitis C virus (HCV) regimen, Abbott Labs (ABT) outlined ...
-
November 12, 2012
Currently, the Nasdaq has declined 0.1%, the S&P 500 is unchanged and the Dow has slipped 0.1%. The recent surge in ...
-
November 12, 2012
The Nasdaq has decreased 0.1%, the S&P 500 has moved little and the Dow is trading down 0.1% so far today. The ...
-
October 29, 2012
Switzerland-based Actelion (ALIOF) recently submitted a New Drug Application (NDA) to the US Food and Drug ...
-
October 24, 2012
Gilead Sciences, Inc.'s (GILD) second-quarter 2012 earnings (excluding special items but including stock option ...
-
October 24, 2012
So far today, the Nasdaq remains relatively unchanged, the S&P 500 has risen 0.1% and the Dow has climbed 0.3%. The ...
-
October 23, 2012
Gilead (Nasdaq:GILD) announced its results for the most recent quarter on October 23, 2012. Gilead Sciences is a ...
-
October 19, 2012
Switzerland-based Actelion (ALIOF) reported third quarter 2012 earnings of $1.17 per American Depository Receipt ...
-
October 18, 2012
Analysts are expecting a drop in profit for Gilead (Nasdaq:GILD) when it reports its results for the third quarter ...
-
October 15, 2012
Arena Pharmaceuticals, Inc. (ARNA) recently initiated a phase I multiple dose study with APD811, which is being ...
-
October 02, 2012
So far today, the Nasdaq has climbed 0.4%, the S&P 500 is up 0.1% and the Dow is trading down 0.2%. The healthcare ...
-
October 01, 2012
It's been a good morning for the market. The Nasdaq has climbed 0.6%; the S&P 500 has increased 0.8%; and the Dow is ...
-
September 26, 2012
Vertex Pharmaceuticals Incorporated (VRTX) and its partner, Alios BioPharma, Inc. recently announced disappointing ...
-
September 17, 2012
The market is down this morning. The Nasdaq is down 0.2%; the S&P 500 is trading down 0.2%; and the Dow has slipped ...
-
September 17, 2012
The market is having a bad day so far: the Nasdaq has slipped 0.2%; the S&P 500 has declined 0.2%; and the Dow is ...
-
September 14, 2012
The market has been doing well after the morning's trading. The Nasdaq has risen 1.1%; the S&P 500 has increased ...
-
September 07, 2012
We are maintaining our Neutral recommendation on Gilead Sciences, Inc. (GILD) with a target price of $61.00. The ...
-
September 05, 2012
The market is on the rise this morning. The Nasdaq has increased 0.2%; the S&P 500 has risen 0.2%; and the Dow is ...
-
August 29, 2012
Gilead Sciences, Inc. (GILD) recently gained US Food and Drug Administration (FDA) approval for its HIV combination ...
